Zymeworks Inc.

NASDAQ:ZYME

Biotechnology

Healthcare
$25.84 -1.64%

-$0.38 today

Market cap
$1.80B
Beta
1.14
P/E (TTM)
-16.6
EPS (TTM)
-$1.37
52W Low $11.51High $29.75

Volume 0.57M

Average 0.71M

ZYME Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Zymeworks Inc.NASDAQ: ZYME

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development grows, but more slowly than its trailing trend

Q3 FY2026 research & development of $36.13M rose 1.5% year over year, behind the +1655.5% change in trailing-twelve-month research & development. Sequentially, it rose 12.8% from the prior quarter. Over 3 fiscal years it compounded at -13.1% a year.

Context

  • Research & development amounted to 129.3% of revenue in FY2025, down 47.1 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +1.5% toward the trailing-twelve-month pace of +1655.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$36.13M+12.8% QoQ
Last fiscal yearDec 2025
$137M+1.8% YoY
LTMSep 2026
$2.51B+1655.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year+1.8%——
3-year CAGR-13.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
137M USD
Year-over-year change
+1.8%
4-year CAGR
-9.0%

Research & Development vs competitors

How ZYME compares with its peers on the latest reported figures

  • ZYME's LTM Sep 2026 research & development of $2.51B is the highest of the 11 companies compared; the peer median is $140.36M.
  • Its year-over-year change of +1655.5% is the highest of 11, against a peer median of +4.6%.
  • Research & development amounts to 942.7% of revenue for ZYME, versus a peer median of 157.2%.
ZYME Competitors Peer median
Research & Development for ZYME and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYMEZymeworks Inc.LTM Sep 2026$2.51B +1655.5%-13.1%942.7%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$283.32M +31.2%+43.9%252960.7%
XNCRXencor, Inc.LTM Jun 2026$255.77M +11.4%+6.3%243.6%
IMNMImmunome, Inc.LTM Sep 2026$236.54M +35.6%+95.7%—
CBIOCrescent Biopharma, Inc.LTM Mar 2026$145.36M +345.0%+69.4%1223.2%
MGNXMacroGenics, Inc.LTM Mar 2026$135.36M -19.9%-12.2%86.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M -15.8%-17.7%119.9%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$69.1M -13.8%-14.9%194.4%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$66.71M -38.5%-7.9%—
CGENCompugen Ltd.LTM Mar 2026$23.92M -1.0%-9.4%32.9%
Peer median (excluding ZYME) $140.36M+4.6%-0.8%157.2%

Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue26.68M412.48M76.01M76.3M105.97M
Cost of Revenue00142.99M00
Gross Profit26.68M412.48M(66.98M)76.3M105.97M
Gross Margin100.0%100.0%-88.1%100.0%100.0%
Research & Development199.75M208.6M143.62M134.62M137M
Selling, General & Admin42.6M73.4M70.4M61.5M61.5M
Operating Expenses242.31M281.95M71.08M213.41M198.5M
Depreciation & Amortization9.58M12M17.31M11.19M11.11M
EBITDA(206.09M)142.49M(120.7M)(108.62M)(68.64M)
EBITDA Margin-772.4%34.5%-158.8%-142.4%-64.8%
Operating Income(215.63M)130.53M(138.05M)(137.11M)(92.54M)
Operating Margin-808.2%31.6%-181.6%-179.7%-87.3%
Interest Income1.97M3.6M19.71M19.94M13.35M
Interest Expense00000
Other Income / Expenses3.27M4.71M18.81M20.5M12.78M
Income Before Tax(212.36M)135.23M(119.24M)(116.61M)(79.75M)
Pre-Tax Margin-795.9%32.8%-156.9%-152.8%-75.3%
Income Tax Expense(516K)10.89M(568K)6.08M1.38M
Net Income(211.84M)124.34M(118.67M)(122.7M)(81.13M)
Net Margin-794.0%30.1%-156.1%-160.8%-76.6%
EPS (Basic)(4.06)1.91(1.72)(1.62)(1.08)
EPS (Diluted)(4.61)1.90(1.72)(1.62)(1.08)
Weighted Avg Shares52.13M65.19M68.86M75.85M75.34M
Weighted Avg Shares (Diluted)52.13M65.25M68.86M75.88M75.34M

Zymeworks Inc.

NASDAQ:ZYME

Intrinsic Alpha fair value

Locked

Current Price

$25.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.